...
首页> 外文期刊>薬理と治療 >Serum Lipid Levels Following Administration of Solid Dispersion Systems of Probucol-polyvinylpyrrolidone in Myocardial Infarction-prone Watanabe Heritable Hyperlipidemic Rabbits
【24h】

Serum Lipid Levels Following Administration of Solid Dispersion Systems of Probucol-polyvinylpyrrolidone in Myocardial Infarction-prone Watanabe Heritable Hyperlipidemic Rabbits

机译:血清脂质水平后培养型丙醇 - 聚乙烯吡咯烷酮在心肌梗死 - 易于Watanabe遗传性高脂血症兔中的固体分散体系

获取原文
获取原文并翻译 | 示例

摘要

Solid dispersion systems of probucol -polyvinylpyrrolidone showed excellent dissolution characteristics and increased bioavailability in normal rabbits. We studied the effect of solid dispersion systems on serum lipid levels to evaluate whether the amount of probucol required might be lesser than that in dosage forms currently available. A solid dispersion system of probucol -polyvinylpyrrolidone (PVP K30)(1:9 weight ratio) were orally administered to myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits for 5 weeks. Serum levels of total cholesterol(T-Cho), triglycerides (TG) and phospholipids (PL) are higher in WHHLMI rabbits than in normal rabbits. Following the administration of solid dispersion systems containing 25 mg of probucol, trough plasma concentrations of probucol were significantly higher for up to 5 weeks than those containing 5 mg of probucol. Signifi-cant decreases in T-Cho, PL, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol were observed following administration of solid dispersion systems containing 25 and 5 mg of probucol. Dose of 5 mg of probucol in rabbits was almost one fifth of the dose of probucol of commercial fine granules in humans by dose per weight.
机译:普ol戊糖醇的固体分散体系 - 聚乙烯基吡咯烷酮显示出优异的溶解特性并增加正常兔的生物利用度。我们研究了固体分散体系对血清脂质水平的影响,评价所需的润性量是否比目前可用的剂型更小。对普罗氏戊酰基吡咯烷酮(PVP K30)(1:9重量比)的固体分散体系口服给予心肌梗死易遗传的高脂血症(WHLMI)兔5周。在WHLMI兔中血清总胆固醇(T-CHO),甘油三酯(TG)和磷脂(PL)的血清水平高于正常兔子。在含有25mg概率的固体分散体系的施用后,润粒血浆浓度明显高达5周,比含有5mg丙醇的矿石。在施用含有25和5mg丙醇的固体分散体系之后,观察到T-Cho,PL,高密度脂蛋白胆固醇和低密度脂蛋白胆固醇中的显着降低。兔子中的5毫克丙醇的剂量几乎是人类商业细颗粒剂量每体重剂量的五分之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号